<DOC>
	<DOCNO>NCT00834119</DOCNO>
	<brief_summary>This Phase 4 , non-comparative , open-label , multi-center study . It design determine effectiveness regular intranasal steroid use alleviate allergic rhinitis nasal symptom , use alone combination oral antihistamine . Subjects receive 200 mcg ( 2 puff nostril ) mometasone furoate day . An oral antihistamine discretion physician may add Day 28 ( Visit 2 ) , patient fail improve nasal symptom .</brief_summary>
	<brief_title>Assessment Intranasal Steroids Allergic Rhinitis When Used Alone Combination With Oral Antihistamine ( Study P03270 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Subjects must demonstrate willingness participate study comply procedure sign write informed consent form Subjects must 1865 year age , either sex race Subjects must diagnose physician moderate severe allergic rhinitis accord ARIA guideline . Subjects must mometasone furoate na√Øve . Significant comorbid medical condition . Respiratory tract infection . Any contraindication accord mometasone furoate product monograph . Patients receive antihistamine treatment within last 5 day . Patients receive corticosteroid treatment within last 30 day . Patients likely require administration systemic steroid course program . Any condition doctor 's opinion could interfere patient completion program . Pregnant lactating patient . Patients local infection involve nasal mucosa . Patients structural abnormality undergo nasal surgery trauma past 6 month . Patients hypersensitivity mometasone furoate allergic corticosteroid . Patients prone nose bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>